---
figid: PMC8992454__cdr-4-965.fig.1
figtitle: Barriers to achieving a cure in lymphoma
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC8992454
filename: cdr-4-965.fig.1.jpg
figlink: /pmc/articles/PMC8992454/figure/fig1/
number: F1
caption: 'B cell signaling pathway. The recognition of antigen by the BCR initiates
  BCR signaling cascade by phosphorylation of CD79, resulting in SRC and non-SRC kinase
  activation. These kinases in proximal BCR signaling phosphorylate signal molecules
  such as BTK, PCLγ2, and BLNK, which form signalosome. DAG produced by PCLγ2 activates
  both Ras-ERK and IKK-NFκB pathways. Another product of PCLγ2, IP3, activates the
  calcium-NFAT pathway. Upon the phosphorylation costimulatory molecule, CD19, the
  activation of the PI3K-AKT pathway is initiated[]. The various drugs targeting this
  pathway are shown, including BTKi, SYKi, SRCi, PI3Ki, mTORi, BTKi, MALT1i, MAPK
  pathway inhibitors, BH3 mimetics, and exportin inhibitors with the targets for these
  drugs highlighted in red. BCR: B-cell receptor; CD79: cluster of differentiation
  79; SRC: proto-oncogene c-SRC; BTKi: Bruton’s tyrosine kinase inhibitor; PCLγ2:
  phospholipase C gamma 2; BLNK: B-cell linker; DAG: diacylglycerol; NFAT: nuclear
  factor of activated T-cells; CD19: cluster of differentiation 19; PI3K-AKT: phosphatidylinositol
  3-kinase-protein kinase B; SYKi: spleen tyrosine kinase; SRCi: proto-oncogene c-Src
  inhibitor; PI3Ki: phosphatidylinositol 3-kinase inhibitor; mTORi: mammalian target
  of rapamycin inhibitor; MALT1i: mucosa-associated lymphoid tissue lymphoma translocation
  1; MAPK: mitogen-activated protein kinase; BH3: B-cell lymphoma-2 homology domain
  3.'
papertitle: Barriers to achieving a cure in lymphoma.
reftext: Swetha Kambhampati, et al. Cancer Drug Resist. 2021;4(4):965-983.
year: '2021'
doi: 10.20517/cdr.2021.66
journal_title: Cancer Drug Resistance
journal_nlm_ta: Cancer Drug Resist
publisher_name: OAE Publishing Inc.
keywords: Lymphoma | drug resistance | novel therapies | targeted agents | immune
  therapies
automl_pathway: 0.8904119
figid_alias: PMC8992454__F1
figtype: Figure
redirect_from: /figures/PMC8992454__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8992454__cdr-4-965.fig.1.html
  '@type': Dataset
  description: 'B cell signaling pathway. The recognition of antigen by the BCR initiates
    BCR signaling cascade by phosphorylation of CD79, resulting in SRC and non-SRC
    kinase activation. These kinases in proximal BCR signaling phosphorylate signal
    molecules such as BTK, PCLγ2, and BLNK, which form signalosome. DAG produced by
    PCLγ2 activates both Ras-ERK and IKK-NFκB pathways. Another product of PCLγ2,
    IP3, activates the calcium-NFAT pathway. Upon the phosphorylation costimulatory
    molecule, CD19, the activation of the PI3K-AKT pathway is initiated[]. The various
    drugs targeting this pathway are shown, including BTKi, SYKi, SRCi, PI3Ki, mTORi,
    BTKi, MALT1i, MAPK pathway inhibitors, BH3 mimetics, and exportin inhibitors with
    the targets for these drugs highlighted in red. BCR: B-cell receptor; CD79: cluster
    of differentiation 79; SRC: proto-oncogene c-SRC; BTKi: Bruton’s tyrosine kinase
    inhibitor; PCLγ2: phospholipase C gamma 2; BLNK: B-cell linker; DAG: diacylglycerol;
    NFAT: nuclear factor of activated T-cells; CD19: cluster of differentiation 19;
    PI3K-AKT: phosphatidylinositol 3-kinase-protein kinase B; SYKi: spleen tyrosine
    kinase; SRCi: proto-oncogene c-Src inhibitor; PI3Ki: phosphatidylinositol 3-kinase
    inhibitor; mTORi: mammalian target of rapamycin inhibitor; MALT1i: mucosa-associated
    lymphoid tissue lymphoma translocation 1; MAPK: mitogen-activated protein kinase;
    BH3: B-cell lymphoma-2 homology domain 3.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IBTK
  - CD79A
  - BCR
  - RN7SL263P
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CD19
  - MS4A1
  - KRT20
  - TNFRSF8
  - PTPRC
  - CD4
  - LCK
  - ZAP70
  - CD247
  - CD3D
  - CD3E
  - CD3G
  - SYK
  - CD28
  - PRKCD
  - LYN
  - SLA
  - SEPSECS
  - DGKZ
  - PTEN
  - MIR17HG
  - MIR18A
  - MIR19A
  - MIR19B1
  - MIR20A
  - MIR92A1
  - PIK3AP1
  - ITPKB
  - BTK
  - IKBKG
  - PLCG1
  - BCL2
  - BCL2L1
  - MCL1
  - PIK3CD
  - CLSTN1
  - PIK3CA
  - VAV1
  - GRB2
  - SOS1
  - CYLD
  - SPATA2
  - PRKCB
  - TRAF3
  - TRAF2
  - TANK
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - KRAS
  - HRAS
  - NRAS
  - PPP3CC
  - INPP5D
  - PDPK1
  - NFATC1
  - NFATC2
  - NFATC3
  - NFATC4
  - NFAT5
  - CARD11
  - TRAF6
  - BCL10
  - MALT1
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - ZC3H12A
  - CRK
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - AKT1
  - AKT2
  - TNIP1
  - TNFAIP3
  - XPO1
  - IKBKB
  - MTOR
  - TLR2
  - MYD88
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - SYT1
  - GORASP1
  - WNK1
  - NFKBIA
  - NFKBIE
  - JUN
  - JUNB
  - JUND
  - FOS
  - FOSB
  - FOSL1
  - FOSL2
  - NFKBID
  - cd79a
  - bcr
  - ighv1-1
  - cd4-1
  - lck
  - zap70
  - ighv1-2
  - syk
  - cd28
  - prkcda
  - prkcdb
  - lyn
  - si:ch73-206d17.1
  - smtla
  - ptenb
  - pik3ap1
  - itpkb
  - btk
  - plcg1
  - bcl2a
  - bcl2l1
  - pik3cd
  - pik3ca
  - grb2b
  - sos1
  - spata2
  - prkcbb
  - traf3
  - rab1ab
  - inpp5d
  - card11
  - traf6
  - bcl10
  - malt1
  - malt2
  - relb
  - zc3h12a
  - mapk8b
  - mapk14a
  - mapk3
  - akt1
  - akt2
  - tnip1
  - tnfaip3
  - xpo1b
  - ikbkg
  - ikbkb
  - mtor
  - pak2a
  - itpka
  - tlr2
  - myd88
  - nfkb1
  - rela
  - nfkbiab
  - nfkbie
  - jun
  - fosab
  - rel
---
